(Q40937490)

25 September 2017

1 reference

title

Lipoprotein(a) in renal disease (English)

1 reference

25 September 2017

0 references

1 reference

Kronenberg F

1

1 reference

25 September 2017

Utermann G

series ordinal

2

1 reference

25 September 2017

Dieplinger H

series ordinal

3

1 reference

25 September 2017

publication date

1 January 1996

1 reference

American Journal of Kidney Diseases

25 September 2017

published in

1 reference

25 September 2017

volume

27

1 reference

25 September 2017

issue

1

1 reference

25 September 2017

page(s)

1-25

1 reference

Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men.

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoproteins and ischaemic heart disease: implications for screening

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

cDNA sequence of human apolipoprotein(a) is homologous to plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Structural relationship of an apolipoprotein (a) phenotype (570 kDa) to plasminogen: homologous kringle domains are linked by carbohydrate-rich regions.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Turnover of lipoprotein (a) in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The mysteries of lipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) and postmenopausal oestrogen

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Identification of 34 apolipoprotein(a) isoforms: differential expression of apolipoprotein(a) alleles between American blacks and whites

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Genetic architecture of the atherogenic lipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) phenotypes, Lp(a) concentration and plasma lipid levels in relation to coronary heart disease in a Chinese population: evidence for the role of the apo(a) gene in coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apo(a) isoforms predict risk for coronary heart disease. A study in six populations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) phenotypes predict the risk for carotid atherosclerosis in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Significant association between low-molecular-weight apolipoprotein(a) isoforms and intermittent claudication

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lp(a) concentration and apo(a) isoform size. Relation to the presence of coronary artery disease in familial hypercholesterolemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Differences in apolipoprotein (a) polymorphism in west Greenland Eskimos and Caucasian Danes

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The apolipoprotein (a) gene: a transcribed hypervariable locus controlling plasma lipoprotein (a) concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotypes to normal lipid variation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Sequence polymorphisms in the apo(a) gene associated with specific levels of Lp(a) in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

A pentanucleotide repeat polymorphism in the 5' control region of the apolipoprotein(a) gene is associated with lipoprotein(a) plasma concentrations in Caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Distribution of apolipoprotein(a) in the plasma from patients with lipoprotein lipase deficiency and with type III hyperlipoproteinemia. No evidence for a triglyceride-rich precursor of lipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) in renal patients: is it a key factor in the high cardiovascular mortality?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Normal lipoprotein(a) concentrations and apolipoprotein(a) isoforms in patients with insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) in diabetic patients and normoglycemic relatives in familial NIDDM

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Plasma lipoprotein (a) concentration and phenotypes in diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) in cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozolol

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The apolipoprotein(a) gene is regulated by sex hormones and acute-phase inducers in YAC transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Fluctuations of plasma lipoprotein-A concentrations during pregnancy and post partum

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Increased concentrations of serum Lp(a) lipoprotein in patients with primary gout

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Thyroid hormone (fT4) reduces lipoprotein(a) plasma levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum lipoprotein(a) levels before and after subtotal thyroidectomy in subjects with hyperthyroidism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated apolipoprotein(a) levels in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The behaviour of lipoprotein(a) in patients with various diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Transient changes of serum lipoprotein(a) as an acute phase protein

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) and acute-phase proteins in acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

A potential basis for the thrombotic risks associated with lipoprotein(a).

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein a inhibits streptokinase-mediated activation of human plasminogen

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein (a) and plasminogen are immunochemically related

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein (a) concentrations are not related to the risk of venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Antifibrinolytic activity of apolipoprotein(a) in vivo: Human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Proliferation of human smooth muscle cells promoted by lipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein Lp(a) and the risk for myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. The ECTIM Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Usefulness of serum lipoprotein (a) as a predictor of restenosis after percutaneous transluminal coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein(a)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

A dominant role of lipoprotein(a) in the investigation and evaluation of parameters indicating the development of cervical atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein and apolipoprotein profile in men with ischemic stroke. Role of lipoprotein(a), triglyceride-rich lipoproteins, and apolipoprotein E polymorphism

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) in patients with carotid atherosclerosis and ischemic cerebrovascular disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) and ischemic cerebrovascular disease in young adults

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

High serum lipoprotein(a) levels are an independent risk factor for cerebral infarction.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The relation of lipoprotein[a] concentrations and apolipoprotein[a] phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Relation of lipoprotein(a) to coronary heart disease and duplexsonographic findings of the carotid arteries in heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum Lp(a) as a discriminant marker of early atherosclerotic plaque at three extracoronary sites in hypercholesterolemic men. The PCVMETRA Group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein[a] as a risk factor for preclinical atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein [Lp(a)] and peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) distribution in a French Canadian population and its relation to intermittent claudication (the Québec Cardiovascular Study)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) genetic polymorphism and serum lipoprotein(a) concentration in patients with peripheral vascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Niceritrol reduces plasma lipoprotein(a) levels in patients undergoing maintenance hemodialysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Effects of erythropoietin therapy on the lipid profile in end-stage renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Reduction of Lp(a) by different methods of plasma exchange

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Influence of apolipoprotein(a) phenotype on lipoprotein(a) quantification: evaluation of three methods

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) in patients with proteinuria

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated lipoprotein (a) levels in primary nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated plasma lipoprotein(a) in patients with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) in nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) serum levels and apolipoprotein(a) phenotypes in children with chronic renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) levels and fibrinolytic activity in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Reduction of lipoprotein(a) following treatment with lovastatin in patients with unremitting nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The increased risk of coronary heart disease associated with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated Lipoprotein(a) Levels in Renal Transplantation and Hemodialysis Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Increased lipoprotein (a) levels in subjects with chronic renal failure on hemodialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Plasma level of lipoprotein Lp(a) is high in predialysis or hemodialysis, but not in CAPD

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein (a) levels in end-stage renal failure and renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein(a) phenotypes and serum lipoprotein(a) levels in maintenance hemodialysis patients with/without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum lipoprotein (a) levels in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) levels in hemodialysis patients: relation to glucose intolerance and hemodialysis duration

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Comparison of Lp(a) concentrations and some potential effects in hemodialysis, CAPD, transplantation, and control groups, and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) levels in chronic renal disease states, dialysis and transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) and treatment of chronic renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum lipoprotein(a) (Lpa(a)) in haemodialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Elevated Lp(a) levels in patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Glucose absorption during continuous ambulatory peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Plasma lipoprotein(a) levels in patients having chronic renal failure with and without diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Alterations of lipoprotein(a) in patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein(a) levels in patients receiving renal replacement therapy: methodologic issues and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Apolipoprotein (a) concentration decreases following renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Cyclosporin and serum lipids in renal transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum levels of lipoprotein (a) after renal transplantation: short-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serum lipoprotein (a) levels in patients with chronic renal failure--evolution after renal transplantation and relationship with other parameters of lipoprotein metabolism: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Effect of immunosuppressive drug regime on cardiovascular risk profile following kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipid and lipoprotein (a) concentrations in renal transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Does cyclosporin increase lipoprotein(a) concentrations in renal transplant recipients?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Does cyclosporin affect lipoprotein(a) concentrations?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Serial changes in blood pressure, renal function, endothelin and lipoprotein (a) during the first 9 days of cyclosporin therapy in males

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Lipoprotein (a) in chronic renal failure patients undergoing hemodialysis: does it have an independent role in the development of further cardiovascular complications?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, and the receptor-associated protein (RAP)

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Further characterization of the cellular plasminogen binding site: evidence that plasminogen 2 and lipoprotein a compete for the same site

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

Localization of apolipoprotein(a) and B-100 in various renal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2896%2990026-8

7 January 2021

10.1016/S0272-6386(96)90026-8

Identifiers

DOI

1 reference

25 September 2017

1 reference